Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SDCBP | O00560 | 3/20 | 0.44 |
| ▸ | SDC2 | P34741 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.42 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23417788 | 0.86 | MME (0.39) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL20793254 | 0.83 | NPSR1 (0.37) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL2574455 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MAPK1FPR2 | |
| SCHEMBL19926834 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MAPK1FPR2 | |
| SCHEMBL19926836 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MAPK1FPR2 | |
| SCHEMBL7419476 | 0.80 | NPSR1 (0.45) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL28712417 | 0.80 | ALDH1A1 (0.45) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL7419479 | 0.80 | NPSR1 (0.45) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL29459492 | 0.79 | NPSR1 (0.44) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL31240964 | 0.79 | NPSR1 (0.44) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174569-A1 | PROCESS PER PREPARING (3a,5a)-20-OXOPREGNAN-3-YL GLYCYL-L-VALINATE HYDROCHLORIDE | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-06-08 | — | — | US | disclosed |
| WO-2020254612-A1 | CONTROLLED-RELEASE TYROSINE KINASE INHIBITOR COMPOUNDS WITH LOCALIZED PD PROPERTIES | Ascendis Pharma Oncology Division A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254613-A1 | CONTROLLED-RELEASE TYROSINE KINASE INHIBITOR COMPOUNDS WITH LOCALIZED PK PROPERTIES | Ascendis Pharma Oncology Division A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254609-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254603-A1 | CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-7531538-B2 | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-6172082-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G. D. SEARLE & CO. | 2001-01-09 | — | — | US | disclosed |
| US-6156768-A | Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6060476-A | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-05-09 | — | — | US | disclosed |
| US-6046190-A | FOR INHIBITING RETROVIRAL PROTEASES SUCH AS HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5968942-A | INHIBITORS OF HIV PROTEASE | G. D. SEARLE & CO. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5843946-A | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-12-01 | — | — | US | disclosed |
| US-5830897-A | AIDS THERAPY | G. D. SEARLE & CO. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5786483-A | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5744481-A | β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0715618-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174569-A1 | PROCESS PER PREPARING (3a,5a)-20-OXOPREGNAN-3-YL GLYCYL-L-VALINATE HYDROCHLORIDE | CYP3A5, CYP17A1, UGT1A3 | NPSR1 3303/4885ALDH1A1 427/4885SDCBP 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.